Uterobag

Therapeutic indications:

The drug is used in cows and sows for the stimulation of labor, prevention of postpartum complications, treatment of retained placenta, uterine atony and hypotonia, as part of combination therapy for endometritis (metritis) and uterine subinvolution, for metritis-mastitis-agalactia syndrome in sows, to increase conception rates, and for embryo recovery in donor cows.

Pharmacotherapeutic group:

Non-selective beta-blockers.

Dosage form description

Solution for intravenous and intramuscular administration. In appearance, the drug is a transparent, colorless to light yellow solution.

Dark glass vials of 100 ml.

Composition of the veterinary drug:

1 ml of the drug contains 5 mg of propranolol hydrochloride as the active substance.

Pharmacological activity:

Propranolol, the active substance of the drug, blocks beta-adrenoceptors in the myometrium, which facilitates the action of endogenous oxytocin, thereby increasing the contractions of the smooth muscles of the uterus and mammary gland. It acts as a catecholamine antagonist. The drug enhances spontaneous and uterotonic-induced uterine contractions, and reduces uterine bleeding during labor and the postoperative period. The drug is well absorbed from the injection site and rapidly distributed throughout the body. The maximum concentration in the blood is reached within 5–10 minutes after administration. Propranolol crosses the blood-brain and placental barriers. It is metabolized in the liver, with some metabolites exhibiting weak beta-blocking activity. The elimination half-life of propranolol is 3–5 hours, and complete elimination takes 12 hours. The drug is excreted from the body predominantly via the urine and partially via the feces in the form of metabolites.

Dosage:

The drug is administered intramuscularly or intravenously. At a dose of 10 ml per animal (50 mg of propranolol hydrochloride per animal), the drug is used:

• in cows for the stimulation of labor and prevention of postpartum complications, as a single dose on the day of calving;
• for retained placenta in cows, three times at 12-hour intervals;
• for uterine subinvolution and endometritis (metritis) in cows, three times at 24-hour intervals in combination with other drugs.

At a dose of 5 ml per animal (25 mg of propranolol hydrochloride per animal), the drug is used:

• for the prevention of metritis-mastitis-agalactia syndrome in sows, as a single dose immediately after farrowing;
• during artificial insemination to increase conception rates in cows and sows, as a single dose 20–30 minutes prior to the procedure;
• for embryo recovery in donor cows, 10–15 minutes prior to flushing.

Contraindications:

Contraindications for use include individual intolerance to the components of the drug, pregnancy, and abnormal fetal presentation.

Overdose:

In case of an overdose, animals may exhibit reduced heart rate, hypotension, bronchospasm, and muscle weakness. If pronounced side effects occur, particularly persistent bradycardia due to overdose, atropine preparations and beta-adrenostimulants (isoprenaline, orciprenaline, etc.) should be administered in accordance with their instructions for use.

Pregnancy and lactation:

The drug is contraindicated during pregnancy and complicated labor (large fetus, fetal malformations, developmental anomalies). Lactating animals should be treated with caution, based on indications and under the supervision of a veterinarian.

Special indications:

No specific effects were observed upon initial administration or discontinuation of the drug. If a dose is missed, the course of treatment should be resumed as soon as possible in accordance with the prescribed dosage and regimen. Do not compensate for a missed dose by increasing the amount administered.

Side effects and individual intolerance:

Adverse events and complications are generally not observed when using the drug in accordance with these instructions. Animals with increased individual sensitivity to the components of the drug may experience allergic reactions. In such cases, administration of the drug should be discontinued, and antihistamines and symptomatic therapy should be prescribed if necessary.

Withdrawal period:

Products obtained from animals treated with the drug may be used for food without restrictions.

Shelf-life:

2 years from the date of manufacture. The drug must not be used after the expiration date.

Storage conditions:

Store in a dark place at temperatures between 2 °C and 25 °C. Keep out of the reach of children. After initial opening of the vial for intramuscular use, it may be stored for 14 days under appropriate storage conditions. For intravenous use, the drug cannot be stored after opening; however, any remaining amount may be used for subsequent intramuscular administration.